EuBiologics KRX:206650KOSDAQ
유바이오로직스 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days0
DART filings, 7 days0
Articles tracked0since Sep 11
In Q2 2026, EuBiologics reported revenue of ₩33.2bn, down 8.3% year on year, and operating profit of ₩8.6bn. EuBiologics (유바이오로직스) appeared in 0 Korean news articles and 0 DART filings over the past seven days.
EuBiologics quarterly results separate, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩33.2bn | -8.3% | ₩8.6bn | ₩7.5bn |
| Q1 2026 | ₩15.6bn | -60.4% | ₩2.2bn | ₩3.7bn |
| Q4 2025 derived | ₩32.3bn | -12.2% | ₩13.6bn | ₩414m |
| Q3 2025 | ₩41.1bn | +13.7% | ₩18.9bn | ₩17.4bn |
| Q2 2025 | ₩36.2bn | +360.6% | ₩11.2bn | ₩7.7bn |
| Q1 2025 | ₩39.5bn | +160.1% | ₩16.9bn | ₩15.7bn |
| Q4 2024 derived | ₩36.8bn | +36.9% | ₩16.6bn | ₩8.2bn |
| Q3 2024 | ₩36.2bn | +216.2% | ₩17.0bn | ₩16.1bn |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases.
EuBiologics top stories 2 weeks, by number of outlets
No story covered by multiple outlets in the past two weeks.
Latest EuBiologics news Korean headlines
No articles yet.